InvestorsHub Logo
Followers 833
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 2279

Tuesday, 08/09/2022 10:44:39 AM

Tuesday, August 09, 2022 10:44:39 AM

Post# of 3011
Re: EDP-235 clinical-trial plans

On yesterday’s CC, Jay Luly may have slipped up by inadvertently revealing that ENTA is seeking to conduct a phase-2/3 trial for EDP-235 (rather than separate phase-2 and phase-3 trials). From the CC transcript:

https://www.fool.com/earnings/call-transcripts/2022/08/09/enanta-pharmaceuticals-enta-q3-2022-earnings-call/

“…generally speaking, the concept on the phase 2 piece would be fairly small and then we would head in to the larger [i.e. phase 3] portion, which would be registrational, obviously.”

I don’t think any of the analysts on the call caught this.

ENTA needs a buy-in from the FDA to run a phase-2/3 trial, of course.

Luly also said that the EUA regulatory pathway for EDP-235 is still open.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News